Lincocin Injection
Lincomycin
300mg/ml
UPJOHN SA
| Pack size | 1ml Vial |
|---|---|
| Dispensing mode | POM |
| Source | BELGIUM |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 6.50 AED |
Indications
Lincocin Injection is used for:
Severe anaerobic infections
Adult Dose
Intravenous
Severe anaerobic infections
Adult:
IM: 600 mg q12-24hr
IV: 600-1000 mg q8-12hr; not to exceed 8 g/day
Child Dose
Intravenous
Severe anaerobic infections
Child:
<1 month old
Safety & efficacy not established
>1 month old
IV: 10-20 mg/kg/day divided q8-12hr
IM: 10 mg/kg q12-24hr
Renal Dose
Renal Impairment, severe: 25-30% of usual dose
Administration
IV Preparation
1000 mg should be diluted in 100 mL or more of D5W, D5 in NS, D10W, or NS
IV Administration
Infusion over 1 hr
Contra Indications
Hypersensitivity to lincomycin or clindamycin
Precautions
Patient w/ history of GI disease particularly colitis, history of asthma or significant allergies. Severe renal and/or hepatic impairment. Pregnancy and lactation. Monitoring Parameters Periodically perform LFTs, kidney function tests and blood cell counts during prolonged therapy.
Pregnancy-Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women; sterile Solution contains benzyl alcohol as a preservative; benzyl alcohol can cross placenta; should be used during pregnancy only if clearly needed; experience with obstetrical patients receiving drug revealed no ill effects related to pregnancy
Animal data
No evidence of teratogenicity when drug administered in diet or via oral gavage to pregnant Sprague Dawley rats during period of major organogenesis at doses up to 5000 mg/kg and 100 mg/kg (approximately 6 times and 0.12 times the maximum recommended human dose [MRHD], respectively, based on body surface area comparison)
Reproduction studies performed in rats administered drug for 2 weeks prior to mating, throughout pregnancy and lactation, revealed no adverse effects on survival of offspring from birth to weaning at doses up to 1000 mg/kg (1.2 times the MRHD based on body surface area comparison) up to 2 generations
Lactation
Drug has been reported to appear in human milk in concentrations of 0.5 to 2.4 mcg/mL; because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing, or to discontinue drug, taking into account importance of drug to mother
Interactions
May potentiate effects of neuromuscular blocking agents (e.g. pancuronium, tubocurarine). Reduced GI absorption w/ kaolin. May antagonise the effect of erythromycin.
Adverse Effects
Side effects of Lincomycin :
Frequency Not Defined
Nausea
Vomiting
Diarrhea
Abdominal pain
Tenesmus
Glossitis
Stomatitis
Pruritus
Angioedema
Serum sickness and anaphylactic or anaphylactoid reactions
Rash
Urticaria
Vaginitis
Exfoliative/vesiculobullous dermatitis
Erythema multiforme
Thrombophlebitis
Erythema
Pain
Swelling
Transient increases in serum bilirubin, alkaline phosphatase, & AST (SGOT) concentrations
Jaundice
Transient leukopenia, neutropenia, eosinophilia
Thrombocytopenia
Agranulocytosis
Headache
Myalgia
Tinnitus
Dizziness
Vertigo
Mechanism of Action
Lincomycin exerts bacteriostatic and bactericidal effects by binding to 50S ribosome subunit. This results in inhibition of protein synthesis, specifically peptide-bond formation in susceptible organisms.
Note
Lincocin 300mg/ml Injection manufactured by UPJOHN SA. Its generic name is Lincomycin. Lincocin is availble in United Arab Emirates.
Farmaco UAE drug index information on Lincocin Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.